Dual GIP/GLP-1 Weight Management
Next-Generation Weight Loss Therapy
Tirzepatide is a dual GIP and GLP-1 receptor agonist—the most powerful FDA-approved weight loss medication available. Clinical trials demonstrated up to 22.5% average body weight reduction, outperforming single-action GLP-1 therapies. Available in T10 and T50 formulations.
22.5%
Avg Body Weight Loss
72
Week Clinical Trial
1x
Weekly Injection
22+
BHRC Locations
Choose Your Formulation
We offer two concentrations to support your weight loss journey from titration through maintenance. Your physician will recommend the best option based on your treatment phase.
10mg per vial
Ideal For
New patients beginning tirzepatide therapy who need lower doses during the 4-week titration intervals.
50mg per vial
Ideal For
Patients who have completed titration and are on therapeutic doses (10mg–15mg weekly) during active weight loss.
The Science
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. Unlike single-action medications, tirzepatide activates two hormone pathways simultaneously for superior weight loss results.
The dual mechanism targets both appetite regulation and metabolic function. GIP activation enhances the effects of GLP-1, resulting in greater satiety, improved blood sugar control, and more significant fat reduction than GLP-1-only medications.
In the SURMOUNT-1 clinical trial, participants on the maximum dose achieved an average of 22.5% body weight loss over 72 weeks—the highest weight reduction ever observed in a phase 3 obesity trial. At BHRC, our physicians guide you through the entire treatment journey.
Book a Consultation
How It Works
Tirzepatide’s dual-action approach delivers superior results through multiple pathways.
Activates GIP receptors to enhance fat metabolism, improve insulin sensitivity, and amplify the weight loss effects of GLP-1—delivering results beyond single-pathway medications.
Stimulates GLP-1 receptors in the brain to reduce appetite, slow gastric emptying, and promote prolonged satiety—helping you feel satisfied with smaller portions.
Improves blood sugar regulation, reduces insulin resistance, and supports healthier lipid profiles—benefits that extend well beyond weight loss alone.
Head-to-Head Results
The SURMOUNT-5 trial directly compared tirzepatide to semaglutide. Tirzepatide demonstrated superior results across all endpoints.
Clinical Benefits
Clinical trials showed participants lost an average of 22.5% of their body weight—47% more than semaglutide in head-to-head trials.
Works on two hormone pathways (GIP + GLP-1) simultaneously for enhanced appetite suppression and metabolic improvement.
Excellent for pre-diabetes prevention with significant improvements in fasting glucose and HbA1c levels.
Studies show improvements in blood pressure, cholesterol, and waist circumference—key cardiovascular risk factors.
Just one injection per week—simple to incorporate into your routine without daily medications or complicated schedules.
SURMOUNT-4 showed 89.5% of patients maintained at least 80% of their weight loss with continued treatment.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Meet with our physician to discuss goals, review health history, and determine if tirzepatide is right for you.
Complete necessary bloodwork to ensure you can safely begin treatment and establish your baseline.
Start at 2.5mg weekly (T10) with increases every 4 weeks to minimize side effects and reach therapeutic dose.
Regular check-ins to monitor progress, transition to T50 when appropriate, and provide nutrition guidance.
Safety & Candidacy
Tirzepatide is FDA-approved for adults with a BMI of 30 or higher, or 27+ with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or cardiovascular disease.
2023
FDA approval for chronic weight management in adults (Zepbound)
SURMOUNT
Comprehensive 6-trial clinical program with 5,000+ participants
Questions
T10 (10mg vial) is designed for the titration phase when you’re on lower doses (2.5mg–7.5mg weekly). T50 (50mg vial) is for patients on therapeutic doses (10mg–15mg weekly) and provides extended supply per vial. Most patients start with T10 during their first 8–12 weeks, then transition to T50 once at therapeutic doses.
Tirzepatide works on two hormone receptors (GIP + GLP-1) while semaglutide only targets GLP-1. In the SURMOUNT-5 head-to-head trial, tirzepatide achieved 20.2% average weight loss compared to 13.7% with semaglutide—47% greater relative weight loss. Your physician can help determine which is best for your goals.
Most patients notice reduced appetite within the first few weeks. Significant weight loss typically becomes visible by weeks 4–8, with results continuing to improve over 6–12 months of treatment. In clinical trials, the greatest weight loss occurred between months 3–9 on therapeutic doses.
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation. These typically occur during dose increases and improve over time. Starting at a low dose (2.5mg with T10) and gradually increasing every 4 weeks helps minimize these effects.
Tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should not be used during pregnancy or breastfeeding. Our physicians will review your complete health history during consultation to ensure this treatment is appropriate for you.
Tirzepatide is typically prescribed as a long-term treatment. The SURMOUNT-4 trial showed that stopping treatment led to weight regain, while continued use maintained and even increased weight loss (25.3% total at 88 weeks). Your physician will work with you to determine the optimal duration based on your goals.
Most patients transition from T10 to T50 once they reach therapeutic doses (10mg+ weekly). This is a normal progression that typically happens after 8–12 weeks of titration. T50 provides more doses per vial, making it more convenient for long-term treatment. Your physician will guide this transition based on your response.
Get Started
Schedule a consultation with our medical team to learn which tirzepatide formulation is right for your health goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*Tirzepatide is FDA-approved for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related condition. Individual results may vary. Common side effects include nausea, diarrhea, vomiting, constipation, and decreased appetite. Not recommended for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. A consultation with our medical team is required to determine if this therapy is appropriate for you.
